Lexpert Ranked Lawyer Profile
 
 
 

Gunars Gaikis
Of Counsel

Smart & Biggar

Gunars Gaikis, Smart & Biggar

Gunars A. Gaikis has over 30 years of experience in IP law and is experienced in the procurement, litigation and enforcement of pharmaceutical and biotechnology patent rights and strategic advising. Gunars has appeared as lead counsel in many precedent setting IP cases before the Ontario, Federal and Supreme Courts, including the June 30, 2017 Supreme Court of Canada decision in AstraZeneca v. Apotex, which struck down the “promise of the patent” utility doctrine. Gunars is recognized as one of the world’s foremost experts in Who’s Who Legal: Thought Leaders 2019. He was named Best Lawyers' 2017 Toronto Biotechnology Law Lawyer of the Year and is recognized amongst the top 30 patent attorneys in the world by Expert Guides: Best of the Best. He is listed in the Lexpert® Guide to the Leading US/Canadian Cross-Border Litigation Lawyers in Canada, The Canadian Legal Lexpert® Directory, Chambers Global, The Best Lawyers in Canada, Benchmark Canada, LMG Life Sciences, Expert Guides: Guide to the World's Leading Patent Law Practitioners, Who's Who Legal: Life Sciences and Patents, MIP's IP Stars Handbook: Patents and IAM Patent 1000. Licensed pharmacist and registered Patent and Trademark Agent. Called to the Ontario Bar in 1983.


Year Called to the Bar:1983 (ON)
150 York St, Suite 1100
Toronto, ON
Phone: (416) 593-5514
Fax: (416) 591-1690
E-mail: ggaikis@smart-biggar.ca

Read more about Gunars Gaikis in...

Big Deals, Suits or Real Estate Transactions

Mentioned in Lexpert Publications

  • Feb 12, 2018
    A look at a landmark case in patent law, in which the so-called “promise doctrine” was struck down by the Supreme Court of Canada
  • May 09, 2016
    Optimism reigns in the life-sciences sector as biologics become a major driver of market growth
  • Dec 01, 2014
    The life sciences sector has seen a huge increase in deal activity that includes regulation, litigation, competition and corporate law, IPOs and M&A work. Optimism reigns in this growing area